Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination of Baricitinib and Anti-TNF vs. Baricitinib in Patients With Rheumatoid Arthritis
NCT04870203Phase 3Active, not recruiting
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jul 2021
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Small Molecules, Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 3 trial of baricitinib, adalimumab, etanercept in rheumatoid arthritis (RA), sponsored by Centre Hospitalier Universitaire de Bordeaux. Started Jul 2021; status: active, not recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04870203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04870203.